Urinary Tract Infection Testing Market Worth $765.6 Million by 2030: Grand View Research, Inc.
SAN FRANCISCO , July 14, 2022 |PRNewswire| -- The global urinary tract infection testing market is expected to reach USD 765.6 million by 2030, according to a new report by Grand View Research, Inc. The UTI testing market is witnessing growth due to factors such as rising disease burden, increasing geriatric population, rapid technological advancements, and high RD investments by key players to introduce novel innovative products, such as self-testing rapid Point-of-Care (PoC) devices products. The global urinary tract infection testing market size was estimated at USD 553.91 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030. Key Industry Insights Findings from the report: Cystitis dominated the market in 2021, with an estimated market share of 41.56%. This can be attributed to the high incidence recurrence rate of cystitis, increased number of product approvals, and the high number of diabetes patients who are more prone to cystitis.
Urinary Tract Infection Testing Market Worth $765.6 Million by 2030: Grand View Research, Inc.
SAN FRANCISCO , July 14, 2022 |PRNewswire| -- The global urinary tract infection testing market is expected to reach USD 765.6 million by 2030, according to a new report by Grand View Research, Inc. The UTI testing market is witnessing growth due to factors such as rising disease burden, increasing geriatric population, rapid technological advancements, and high RD investments by key players to introduce novel innovative products, such as self-testing rapid Point-of-Care (PoC) devices products. The global urinary tract infection testing market size was estimated at USD 553.91 million in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030. Key Industry Insights Findings from the report: Cystitis dominated the market in 2021, with an estimated market share of 41.56%. This can be attributed to the high incidence recurrence rate of cystitis, increased number of product approvals, and the high number of diabetes patients who are more prone to cystitis.